ROCKVILLE, Md., March 27 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael Polymeropoulos, M.D., Vanda President and CEO will present at the Annual Meeting of the International Congress on Schizophrenia Research in Colorado Springs, Colorado on March 30th.
The workshop, titled “Genetics in Psychiatry: From Basic Science to the Bedside -- Opportunities and Obstacles” will take place on Friday, March 30, 2007, from 6:00 p.m. to 7:30 p.m. Mountain Time. The company will highlight the practical application of pharmacogenetics to the treatment of schizophrenia and present genetic association studies of novel genetic predictors of QTc prolongation from the iloperidone clinical development program, including the thorough QTc safety study (2328) and the recently completed iloperidone Phase III efficacy study (3101).
About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda’s second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda’s third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness and is ready for a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Vanda Pharmaceuticals Inc.
CONTACT: Steven A. Shallcross, Senior Vice President & CFO of VandaPharmaceuticals Inc., +1-240-599-4500, steven.shallcross@vandapharma.com;Daniel Budwick of BMC Communications Group, +1-212-477-9007 ext. 14,dbudwick@bmccommunications.com, for Vanda Pharmaceuticals Inc.
Web site: http://www.vandapharma.com/
